Hypoxemia

Beyond Cancer, Ltd. Appoints Susan Howell Jones, CPA as Chief Financial Officer

Retrieved on: 
Martedì, Maggio 17, 2022
Hotel manager, CPA, Urinary tract infection, Death, American Association for Cancer Research, Operation Accountability, Company, Immunotherapy, Atmosphere of Earth, Pulmonary hypertension, Radiation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, R, Director, Hypoxemia, Patient, Nontuberculous mycobacteria, BASF, NASDAQ, Nitric oxide, AACR, Pulmonology, Wilms' tumor, Clinical trial, Association, NO, Summit, COVID-19, Failure, Adult, Respiratory distress syndrome, Deloitte, NTM, Research, UNO, Time, Ultra, Toxicity, Board, Sumitomo Corporation, Safety, American Association, LLC, Acquisition, Operational definition, Interim, GLOBE, Management, Pharmaceutical industry, Medical imaging, Cancer, American Cyanamid

Following her tenure at BASF, Ms. Jones joined Summit Agro USA, LLC, a start-up and subsidiary of Sumitomo Corp., as Chief Financial Officer.

Key Points: 
  • Following her tenure at BASF, Ms. Jones joined Summit Agro USA, LLC, a start-up and subsidiary of Sumitomo Corp., as Chief Financial Officer.
  • During her 6-year tenure at Summit, she helped the company progress from R&D phase to commercial stage with aggressive revenue growth of over 1,000%.
  • Most recently she served as Interim Chief Financial Officer at dPIX, LLC, a semiconductor producer for medical and aerospace industries.
  • I would like to welcome Susan to the Company on behalf of the Board of Directors and the entire Beyond Cancer team, commented Selena Chaisson, Chief Executive Officer of Beyond Cancer.

Vapotherm to Report First Quarter 2022 Financial Results

Retrieved on: 
Lunedì, Maggio 2, 2022
Other Manufacturing, Technology, Textiles, Other Technology, Manufacturing, Cardiology, Other Health, Health, General Health, Regulation Fair Disclosure, Breathe Me, Telephone, Company, NYSE, Gas, Regulation, Patient, Security (finance), Hypoxemia, VAPO, Investor relations, U.S. Securities and Exchange Commission, Investor, Pharmaceutical industry, Vapotherm

Vapotherm, Inc. (NYSE: VAPO) (Vapotherm or the Company), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the first quarter of 2022 after the close of trading on Wednesday, May 4, 2022.

Key Points: 
  • Vapotherm, Inc. (NYSE: VAPO) (Vapotherm or the Company), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the first quarter of 2022 after the close of trading on Wednesday, May 4, 2022.
  • ET to discuss the financial results and recent business developments.
  • To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.vapotherm.com/events-and-presentations/events .
  • The webcast replay will be available on the Vapotherm website for 90 days following completion of the call.

Beyond Air® Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022

Retrieved on: 
Lunedì, Aprile 25, 2022
EMA, Nitric oxide, NTM, Respiratory syncytial virus, Marketing, Pulmonology, Artery, Population, COVID-19, Adult, RSV, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ben-Gurion University of the Negev, Annual report, Urinary tract infection, Nontuberculous mycobacteria, Bacteria, Mycobacterium, Food, Outline of health sciences, Patient, Fungus, CAVP, Parasitism, Atmosphere of Earth, Technology, Company, SEC, Forward-looking statement, Faculty, McMaster Faculty of Health Sciences, Bronchiolitis, Mark (given name), Pulmonary hypertension, Safety, Hypoxemia, Beersheba, Policy, Respiratory distress syndrome, FDA, PAS, Virus, NO, Time, NO2, Pharmaceutical industry, Vaccine

The Beyond Air team continues to execute in this challenging pandemic environment and move the Beyond Air pipeline forward.

Key Points: 
  • The Beyond Air team continues to execute in this challenging pandemic environment and move the Beyond Air pipeline forward.
  • Professor, Head of Department Pediatrics, Soroka University Medical Center; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Dr. Goldbart presented the results of the long-term study at the PAS 2022 Meeting in an oral presentation titled, 1179165 Long-term effects of inhaled nitric oxide in infants with bronchiolitis a multi center study.
  • The presentation is available on the Events page of the Beyond Air website ( click here ).

Vapotherm Announces Preliminary Revenue for First Quarter of 2022 and Withdraws 2022 Annual Guidance

Retrieved on: 
Mercoledì, Aprile 6, 2022
Biotechnology, Other Manufacturing, General Health, Health, Medical Devices, Hospitals, Manufacturing, Other Health, EBITDA, Hospital, Company, Private Securities Litigation Reform Act, Adoption, Gas, Risk, Regulation, Virulence, Patent, NYSE, Oxygen, SEC, Investor relations, CEO, Hypoxemia, Failure, Food, Security (finance), Omicron, Technology, Food and Drug Administration, HVT, COVID-19, U.S. Securities and Exchange Commission, RSV, VAPO, Breathe Me, Regulation Fair Disclosure, Patient, Video game, Pharmaceutical industry, Vapotherm

Vapotherm, Inc. (NYSE: VAPO) (Vapotherm or the Company), today announced preliminary unaudited revenue for the quarter ended March 31, 2022.

Key Points: 
  • Vapotherm, Inc. (NYSE: VAPO) (Vapotherm or the Company), today announced preliminary unaudited revenue for the quarter ended March 31, 2022.
  • The Company also announced withdrawal of its full year 2022 revenue guidance (issued on January 12, 2022 and reiterated on February 24, 2022) together with its full year 2022 gross margin, operating expense and adjusted EBITDA guidance.
  • Preliminary revenue for the first quarter of 2022 is expected to be in the range of $20.5 million to $21.5 million, compared to $32.3 million for the first quarter of 2021.
  • Vapotherm plans to release financial results for the first quarter of 2022 after the close of trading on Wednesday, May 4, 2022.

Beyond Cancer™ to Present Two Abstracts for Ultra-High Concentration Nitric Oxide Therapy at the 2022 AACR Annual Meeting

Retrieved on: 
Martedì, Marzo 8, 2022
Virus, NASDAQ, Time, Mycobacterium, Section 32, AACR, Metastasis, Nontuberculous mycobacteria, Company, Breast, Marketing, Colon, FDA, Artery, Respiratory distress syndrome, Section 24 of the Canadian Charter of Rights and Freedoms, Annual report, Cancer, Urinary tract infection, Nitric oxide, Wilms' tumor, EMA, Atmosphere of Earth, New Orleans Morial Convention Center, AM, Policy, UNO, Forward-looking statement, PM, Pulmonology, GLOBE, Bacteria, Radiation, Patient, American Association, NO, 2021 Essex County Council election, Pulmonary hypertension, Technology, Fungus, COVID-19, Immunotherapy, Death, SEC, Association, Hypoxemia, Parasitism, Adult, NTM, American Association for Cancer Research, Pharmaceutical industry, Fuel oil, Medical imaging

In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs.

Key Points: 
  • In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs.
  • Cancer is the second leading cause of death globally, with tumor metastases responsible for approximately 90% of all cancer-related deaths.
  • Nitric oxide at ultra-high concentrations has been reported to show anticancer properties and to serve as a chemosensitizer and radiotherapy enhancer.
  • Based on its current findings, Beyond Cancer is developing treatment protocols using ultra-high nitric oxide concentrations to ablate primary tumors and treat metastatic disease.

Global $1.4 Billion Ventilators Market (2021 to 2026) - Development of Non-Invasive and Microprocessor-Controlled Portable Ventilators Creates Opportunities - ResearchAndMarkets.com

Retrieved on: 
Venerdì, Febbraio 18, 2022
Medical Devices, Health, ICU, Degenerative disease, Hospital, Patient, Bed, Intensive care medicine, Growth, Volume, Incidence, Prevalence, Hypoxemia, ACC, Sleep, Adult, Coronavirus, Clinic, Conditional sentence, Lists of diseases, Population, USD, Emergency medical services, Ventilation, COPD, COVID-19, Proning, Pressure, Home care in the United States, CAGR, Chronic obstructive pulmonary disease, Sleep apnea, Smoker, Poultry, Pharmaceutical industry, Heating, ventilation, and air conditioning

The ventilators market is projected to reach USD 1.9 billion in 2026 from USD 1.4 billion in 2021, at a CAGR of 7.6% during the forecast period.

Key Points: 
  • The ventilators market is projected to reach USD 1.9 billion in 2026 from USD 1.4 billion in 2021, at a CAGR of 7.6% during the forecast period.
  • Over the years, the ventilators market has evolved significantly due to technological advancements, such as developing advanced portable ventilators and improvements in the sensor technologies used in ventilators.
  • The ability of combined-mode ventilation to provide both modes of ventilation makes it a desirable product in the ventilators market.
  • The ventilators market in North America dominated the ventilators market in the forecast period.

Vapotherm to Report Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Giovedì, Febbraio 10, 2022
Medical Devices, Other Health, Health, Science, Research, NYSE, Regulation, Patient, Regulation Fair Disclosure, Company, Breathe Me, VAPO, Hypoxemia, Security (finance), U.S. Securities and Exchange Commission, Telephone, Gas, Investor, Investor relations, Pharmaceutical industry, Vapotherm

ET to discuss the financial results and recent business developments.

Key Points: 
  • ET to discuss the financial results and recent business developments.
  • To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.vapotherm.com/events-and-presentations/events .
  • The webcast replay will be available on the Vapotherm website for 90 days following completion of the call.
  • Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA.

Global Oxygen Therapy Market Report 2021-2026: Increasing Prevalence of Various Respiratory Disorders, Such as Pneumonia, CF, Asthma, Dysplasia and Sleep Apnea Creates Positive Outlook - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Gennaio 27, 2022
General Health, Medical Devices, Hospitals, Health, Medical Supplies, Oxygen, Physician, Surgeon, Pneumonia, Asthma, COVID-19, POC, Nicotine, Prevalence, Hypoxia, Research, Degenerative disease, Carbon, Cannula, Blood, Dysplasia, Efficiency, Industry, Cystic fibrosis, Sleep apnea, Smokeless tobacco, Hypoxemia, Patient, CAGR, R, Health care, Beauty salon, Hospital, Pharmaceutical industry, Potash, Growth

The "Oxygen Therapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oxygen Therapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • Looking forward, the global oxygen therapy market to grow at a CAGR of around 10% during the forecast period (2021-2026).
  • Oxygen therapy, or supplemental oxygen, refers to a medical treatment that involves using an additional oxygen source to manage the blood oxygen levels and prevent carbon monoxide toxicity.
  • Additionally, the development of cost-effective, rapid and accurate oxygen therapy devices and the increasing preference for oxygen therapy among doctors, physicians, surgeons and patients are also creating a positive outlook for the market.

Vapotherm Reports Preliminary Fourth Quarter and Full Year 2021 Revenue Results

Retrieved on: 
Mercoledì, Gennaio 12, 2022
Technology, General Health, Health, Other Technology, Patient, Investor relations, Private Securities Litigation Reform Act, SEC, Breathe Me, Gold, COVID-19, NYSE, U.S. Securities and Exchange Commission, CEO, Regulation Fair Disclosure, Review, Regulation, HVT, Gas, Company, Food and Drug Administration, Risk, Hospital, Food, Patent, Hypoxemia, Security (finance), Failure, Investment, VAPO, Pharmaceutical industry, Animal, Vapotherm

Preliminary net revenue for the fourth quarter of 2021 is expected to be approximately $21.8 million, a two-year compounded annual growth rate of approximately 29%.

Key Points: 
  • Preliminary net revenue for the fourth quarter of 2021 is expected to be approximately $21.8 million, a two-year compounded annual growth rate of approximately 29%.
  • Preliminary net revenue for the full year 2021 is expected to be approximately $112.8 million, a two-year compounded annual growth rate of approximately 53%.
  • The Company plans to release its fourth quarter and full year 2021 financial results in late February 2022.
  • These preliminary net revenue results are based on current expectations.

Worldwide Bronchiolitis Industry to 2030 - Featuring Immunotek, Sanofi and AstraZeneca Among Others - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Dicembre 9, 2021
Biotechnology, Pharmaceutical, Health, Other Health, Hyponatremia, Awareness, Review, Technology, Respiratory rate, Hospital, Therapy, DC, Disease, Hypoxemia, TLR, Bacteria, NLR, Dehydration, News, Comprehension, USD, Ribavirin, Palivizumab, RSV, Table, Immunity, Infection, United Kingdom, Pharmaceutical industry, Vaccine, Renewable energy

The Bronchiolitis market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Bronchiolitis symptoms market size from 2018 to 2030 segmented by seven major markets.

Key Points: 
  • The Bronchiolitis market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Bronchiolitis symptoms market size from 2018 to 2030 segmented by seven major markets.
  • The report also covers current Bronchiolitis symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities.
  • The drug chapter segment of the report encloses detailed analysis of Bronchiolitis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Bronchiolitis.